The CPT code for a Lupron (leuprolide acetate) injection is 96372 when the indication is endometriosis (N80.x), uterine fibroids (D25.x) or central precocious puberty (E30.1), and 96402 when the indication is prostate cancer (C61) — CPT classifies a GnRH agonist given for cancer as a hormonal anti-neoplastic chemotherapy administration, not a plain therapeutic injection, and 96402 pays roughly twice the 96372 rate. The drug bills one of two HCPCS codes depending on the kit: the 3.75 mg and 11.25 mg gynecologic kits, and every Lupron Depot-PED kit, are J1950, per 3.75 mg; the 7.5 mg, 22.5 mg, 30 mg and 45 mg prostate-cancer kits are J9217, per 7.5 mg — the same code as Eligard. Match the NDC on the dispensed kit to CMS’s ASP NDC-HCPCS crosswalk before coding the claim. Modifier JZ is appropriate on either code because every kit is a single-dose container with no partial dose possible.
Lupron Depot is always given intramuscularly, so the administration code never depends on the dose or the interval — only on why the drug was given. CPT carries two different injection codes that both fit an IM leuprolide shot, and picking between them is a diagnosis question, not a pharmacy question:
96372 — “Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular”
96402 — “Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic” — AMA CPT 2026, codes 96372 and 96402
A GnRH agonist used to treat prostate cancer (C61) meets CPT’s hormonal anti-neoplastic definition, so the injection is 96402 — even though nothing about the needle, the syringe or the drug volume is different from an endometriosis dose. The same drug used for endometriosis, uterine fibroids before surgery, or central precocious puberty is not treating a neoplasm, so it is the ordinary therapeutic injection code, 96372. Submitting 96402 with N80.x, D25.x or E30.1 denies for CPT/ICD-10 incompatibility — a chemotherapy administration code paired with a non-oncology diagnosis; the fix is to resubmit with 96372. The reverse error, 96372 on a C61 claim, does not usually deny outright but underpays the encounter, since 96372’s administration RVU runs well below 96402’s.
Two codes that do not apply here: 96401 (chemotherapy administration, SC/IM, non-hormonal) is for cytotoxic or monoclonal antineoplastics, not a hormonal agent like leuprolide, and 96413 (chemo IV infusion) never applies because Lupron Depot is not given intravenously. If a claim shows 96413 or 96401 next to a J1950 or J9217 line, the administration code is wrong regardless of the diagnosis.
Lupron Depot bills two HCPCS codes depending on the kit, not one code at every strength. The 3.75 mg (1 unit) and 11.25 mg (3 units) gynecologic kits, and every Lupron Depot-PED kit, bill J1950, per 3.75 mg. The 7.5 mg (1 unit), 22.5 mg (3 units), 30 mg (4 units) and 45 mg (6 units) prostate-cancer kits bill J9217, per 7.5 mg — the same code as Eligard, a chemically identical but separately manufactured (Tolmar) subcutaneous depot in the same 7.5/22.5/30/45 mg strengths. CMS’s ASP NDC-HCPCS crosswalk assigns each Lupron Depot NDC to one of the two codes; match the NDC on the kit dispensed, not just the mg strength — that is what settles “what J-code for Lupron 22.5 mg”: J9217 × 3, not J1950. The administration code follows the diagnosis (96372 for N80.x/D25.x/E30.1; 96402 for C61); the HCPCS code follows the kit, and the two questions are independent of each other.
Lupron Depot-PED, the pediatric central precocious puberty formulation, follows the 3.75 mg unit basis under J1950: the 7.5 mg kit is 2 units, the 11.25 mg kit is 3 units, and the 15 mg kit is 4 units. JZ is appropriate on either code, J1950 or J9217, because every kit is a pre-filled single-dose syringe-and-diluent kit that delivers one fixed depot dose with nothing left to discard. CMS’s claim-processing edit enforces JW/JZ on J9217, which is on CMS’s JW/JZ Modifier Policy HCPCS Codes list; J1950 is not on that list, so the edit does not fire on a J1950 line — appending JZ there is still correct, just not systematically enforced. The MUE for J9217 is 6 units per day (practitioner and facility, MAI 3) — exactly the 45 mg six-month prostate-cancer kit, so no single legitimate adult depot dose exceeds it. The MUE for J1950 is 12 units per day — that ceiling belongs to the Lupron Depot-PED 45 mg, six-month kit, not an adult prostate-cancer depot, since every adult 7.5–45 mg strength now bills J9217. If a claim carries more than 6 units of J9217 or 12 units of J1950 on one date of service, that is either two kits given the same day (unusual and needs its own documentation) or a units-math error, not a normal claim.
One nuance worth stating plainly: the unit count follows the kit dispensed, not the interval it is meant to cover. An 11.25 mg kit is a single-dose container built to cover a three-month gap, but if it is administered at a one-month follow-up instead of the labeled three-month schedule, the claim still bills J1950 × 3 with JZ — the whole kit went into the patient in one injection, so nothing was discarded, regardless of how the next dose is timed. JZ and JW attach to what left the vial or syringe that day, never to the treatment calendar.
A Lupron Depot visit whose only content is the injection bills 96372 or 96402 alone — never with 99211. The nurse-only visit code is bundled into the injection administration code with a modifier indicator that blocks it from paying separately in the office, with or without modifier 25, so a claim carrying both 96372 (or 96402) and 99211 on the same date will have the 99211 denied. An established-patient E/M is billable the same day only when the physician performs and documents a significant, separately identifiable service beyond the decision to inject — a new symptom worked up, a medication reconciled, a comorbidity managed — and in that case modifier 25 goes on the E/M code, never on 96372 or 96402. See the 99214 with 96372 page for the documentation standard that supports the modifier; the same rule applies unchanged when the injection code is 96402 instead of 96372.
Both claims price out through the Code this visit tool; changing the diagnosis and dose there reproduces both lines above. The units calculator does the 3.75 mg math for the gynecologic kits; the same tool at the J9217 basis gives 22.5 mg → 3 units for the prostate kits.
96372. Endometriosis (N80.x) is not an oncology indication, so the intramuscular Lupron Depot injection bills the standard therapeutic injection code, not the chemotherapy administration code 96402 reserved for the prostate-cancer indication.
J9217, at 3 units (22.5 ÷ 7.5). The 22.5 mg kit is one of the prostate-cancer strengths — 7.5, 22.5, 30 and 45 mg — that CMS’s ASP NDC-HCPCS crosswalk assigns to J9217, the same code as Eligard. J1950, per 3.75 mg, is the code for the 3.75 mg and 11.25 mg gynecologic kits and the Lupron Depot-PED kits, not the 22.5 mg kit.
C61 (malignant neoplasm of prostate) is the diagnosis that supports 96402 for the injection. Pair it with J9217 at the dose-appropriate unit count (1/3/4/6 units for the 7.5/22.5/30/45 mg kits) — the prostate-cancer strengths bill J9217, not J1950. N80.x, D25.x and E30.1 are non-oncology indications and pair with 96372 and J1950 instead, never with 96402.
Not 99211 — it is bundled into 96372 and 96402 with no modifier that unbundles it. A higher-level E/M (99213-99215) is billable the same day only when the visit included a significant, separately identifiable service beyond the injection decision, documented in the note, with modifier 25 on the E/M line.
Quoted passages are reproduced from the cited federal publications; everything else is our reading of them. The methodology by which we resolve source disagreements is described in the Methodology.